CMXHF Stock - CSL Limited
Unlock GoAI Insights for CMXHF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $15.43B | $14.80B | $13.17B | $10.49B | $10.27B |
| Gross Profit | $7.95B | $7.56B | $6.71B | $5.66B | $5.74B |
| Gross Margin | 51.5% | 51.1% | 50.9% | 54.0% | 55.9% |
| Operating Income | $2.96B | $3.81B | $2.90B | $2.92B | $2.59B |
| Net Income | $3.00B | $2.64B | $2.19B | $2.25B | $1.78B |
| Net Margin | 19.5% | 17.9% | 16.7% | 21.5% | 17.4% |
| EPS | $6.20 | $5.47 | $4.55 | $4.81 | $3.94 |
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Visit WebsiteEarnings History & Surprises
CMXHFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 10, 2026 | — | — | — | — |
Q3 2025 | Aug 18, 2025 | $2.62 | $1.38 | -47.3% | ✗ MISS |
Q1 2025 | Feb 11, 2025 | $4.41 | $2.56 | -42.0% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $1.80 | $1.83 | +1.7% | ✓ BEAT |
Q2 2024 | Apr 11, 2024 | $4.07 | $2.78 | -31.7% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $1.67 | $0.82 | -51.1% | ✗ MISS |
Q4 2022 | Dec 30, 2022 | $3.50 | $2.36 | -32.6% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | $1.09 | $0.63 | -42.3% | ✗ MISS |
Q4 2021 | Dec 30, 2021 | $3.40 | $2.76 | -18.8% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | $1.09 | $0.61 | -43.9% | ✗ MISS |
Q4 2020 | Dec 30, 2020 | $3.12 | $2.13 | -31.7% | ✗ MISS |
Q2 2020 | Jun 30, 2020 | $1.92 | $1.06 | -44.8% | ✗ MISS |
Q4 2019 | Dec 30, 2019 | $2.68 | $1.43 | -46.6% | ✗ MISS |
Q2 2019 | Jun 30, 2019 | — | $1.17 | — | — |
Q4 2018 | Dec 31, 2018 | — | $1.97 | — | — |
Q2 2018 | Jun 30, 2018 | — | $1.41 | — | — |
Q4 2017 | Dec 31, 2017 | — | $2.36 | — | — |
Q2 2017 | Jun 30, 2017 | — | $1.16 | — | — |
Q4 2016 | Dec 31, 2016 | — | $1.76 | — | — |
Q2 2016 | Jun 30, 2016 | — | $1.14 | — | — |
Latest News
Frequently Asked Questions about CMXHF
What is CMXHF's current stock price?
What is the analyst price target for CMXHF?
What sector is CSL Limited in?
What is CMXHF's market cap?
Does CMXHF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CMXHF for comparison